Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 50 of 129 publications.

Skelsey MK, Okun MM, Schiro J, Dozier S, Glinert R, Boeri M. Patients' willingness to accept adverse event and cost trade-offs for reduced risk of non-melanoma skin cancer. Presented at the 2022 American Society for Dermatologic Surgery Annual Meeting; October 6, 2022. Aurora, CO.

Poulos C, Boeri M, Coulter JR, Huang L, Schley K, Pugh SJ. Travelers' preferences for tick-borne encephalitis vaccination. Expert Rev Vaccines. 2022 Oct 1;21(10):1495-504. doi: 10.1080/14760584.2022.2108798

Feldman SR, Thyssen JP, Boeri M, Gerber R, Neary MP, Cha A, Hauber B, Cappelleri JC, Xenakis J, Leach C, Zeichner J. Preferences for topical treatments in patients with mild-to-moderate atopic dermatitis. Poster presented at the 31st EADV Congress; September 7, 2022. Milan, Italy.

Vass CM, Boeri M, Poulos C, Turner AJ. Matching and weighting in stated preferences for health care. Journal of choice modelling. 2022 Sep;44. doi: 10.1016/j.jocm.2022.100367

Boeri M, Hauber B, Cappelleri JC. Considerations around coding the membership probability function in a latent class analysis: renewed insights. Pharmacoeconomics. 2022 Jul;40(7):653-61. doi: 10.1007/s40273-022-01155-5

Dobra R, Davies JC, Elborn JS, Kee F, Boeri M. A discrete choice experiment to quantify the influence of trial features on patients' decisions to join cystic fibrosis clinical trials. Poster presented at the 45th European Cystic Fibrosis Society Conference; June 8, 2022. Rotterdam, The Netherlands.

AlHarbi O, Farsakh NA, Al-Awadhi A, Al-Taweel T, Mikhail I, Batwa F, Bedran K, Balkan D, Cappelleri JC, Boeri M, Habjoka S, Mosli M. Patient preferences for ulcerative colitis treatment in the middle east region: results from a discrete-choice experiment. Poster presented at the 2022 Digestive Disease Week; May 21, 2022. San Diego, CA.

Johnson R, Boeri M, Gonzalez J. Do we really need another preference study? Using benefit-transfer methods to increase use of patient-preference data in decision making. Presented at the ISPOR 2022 Conference; May 17, 2022. Washington, DC.

Vass CM, Boeri M, Karim S, Marshall D, Craig B, Ho KA, Mott D, Ngorsuraches S, Badawy SM, Mühlbacher A, Gonzalez JM, Heidenreich S. Accounting for preference heterogeneity in discrete-choice experiments: an ISPOR Special Interest Group Report. Value Health. 2022 May;25(5):685-94.

Walsh DA, Boeri M, Abraham L, Atkinson J, Bushmakin AG, Cappelleri JC, Hauber B, Klein K, Russo L, Viktrup L, Turk D. Exploring patient preference heterogeneity for pharmacological treatments for chronic pain: a latent class analysis. Eur J Pain. 2022 Mar;26(3):648-67. doi: 10.1002/ejp.1892

McMichael AJ, Kane JPM, Rolison JJ, O'Neill FA, Boeri M, Kee F. Implementation of personalised medicine policies in mental healthcare: results from a stated preference study in the UK. BJPsych Open. 2022 Feb 3;8(2):e40. doi: 10.1192/bjo.2022.9

Jones L, Boeri M, Christie M, Durance I, Evans KL, Fletcher D, Harrison L, Jorgensen A, Masante D, McKinlay J, Paterson DM, Schmucki R, Short C, Small N, Southon G, Stojanovic T, Waters R. Can we model cultural ecosystem services, and are we measuring the right things? People Nat. 2022 Feb;4(1):166-79. doi: 10.1002/pan3.10271

Rosenow F, Winter Y, Leunikava I, Brunnert M, Joeres L, Sutphin J, Boeri M, Smith J, Villani F, Brandt C. Relative importance of clinical outcomes and safety risks of antiseizure medication monotherapy for patients and physicians: discrete choice experiment eliciting preferences in real-world study "VOTE". Epilepsia. 2022 Feb;63(2):451-62. doi: 10.1111/epi.17137

Dorgali MV, Longo A, Vass C, Shields G, Harrison R, Scarpa R, Boeri M. A general public study on preferences and welfare impacts of antimicrobial resistance in the United Kingdom. Pharmacoeconomics. 2022 Jan;40(1):65-76. doi: 10.1007/s40273-021-01076-9

Boeri M, Purdum AG, Sutphin J, Hauber B, Kaye JA. CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma: physician preferences trading off benefits, risks and time to infusion. Future Oncol. 2021 Dec;17(34):4697-709. doi: 10.2217/fon-2021-0160

Dobra R, Elborn JS, Madge S, Allen L, Boeri M, Kee F, Goundry S, Purcell T, Saunders C, Davies JC. Guiding the rational design of patient-centred drug trials in cystic fibrosis: a Delphi study. J Cyst Fibros. 2021 Nov;20(6):986. doi: 10.1016/j.jcf.2021.03.021

Gonzalez JM, Boeri M. The impact of the risk functional form assumptions on maximum acceptable risk measures. Patient. 2021 Nov;14(6):827-36. doi: 10.1007/s40271-021-00518-y

Montgomery ET, Browne E, Atujuna M, Boeri M, Mansfield C, Sindelo S, Hartmann M, Ndwayana S, Bekker LG, Minnis A. Long-acting injection and implant preferences and trade-offs for HIV prevention among South African male youth. J Acquir Immune Defic Syndr. 2021 Jul 1;87(3):928-36. doi: 10.1097/QAI.0000000000002670

Vass CM, Boeri M, Poulos C, Turner AJ. Matching and weighting in health preference research. Presented at the 2021 Virtual 12th Meeting of the International Academy of Health Preference Research; June 2021. [abstract] Patient. 2021 Jun 18; p.1-6. doi: 10.1007/s40271-021-00532-0

Heidenreich S, Boeri M, Hess S, Janssen E. Accounting for preference heterogeneity in stated preference studies: moving from methods to practice to decision making – the issue of developing useful guidance. Presented at the Virtual ISPOR 2021 Conference; May 2021.

Dobra RA, Boeri M, Elborn S, Kee F, Madge S, Davies JC. Discrete choice experiment (DCE) to quantify the influence of trial features on the decision to participate in cystic fibrosis (CF) clinical trials. BMJ Open. 2021 Mar 2;11(3):e045803. doi: 10.1136/bmjopen-2020-045803

Feldman SR, Poulos C, Gilloteau I, Mange B, Boehm K, Boeri M, Naatz M, Augustin M. Exploring determinants of psoriasis patients' treatment choices: a discrete-choice experiment study in the United States and Germany. J Dermatolog Trea. 2021 Feb 3;1-10. doi: 10.1080/09546634.2020.1839007

Boeri M, Saure D, Schuster C, Hill J, Guerreiro M, Klein K, Hauber B. Impact of clinical and demographic characteristics on patient preferences for psoriasis treatment features: results from a discrete-choice experiment in a multicountry study. J Dermatolog Trea. 2021 Jan 7;33(3):1598-605. doi: 10.1080/09546634.2020.1869145

Carroll J, Aravena C, Boeri M, Denny E. "Show me the energy costs": short and long-term energy cost disclosure effects on willingness-to-pay for residential energy efficiency. Energy J. 2021;43(3):133-52. doi: 10.5547/01956574.43.3.jcar

Vass CM, Boeri M. Mobilising the next generation of stated-preference studies: the association of access device with choice behaviour and data quality. Patient. 2021 Jan;14(1):55-63. doi: 10.1007/s40271-020-00484-x

Rosenow F, Winter Y, Leunikava I, Brunnert M, Sutphin J, Boeri M, Villani F, Brandt C. Patient and physician preferences in epilepsy monotherapy in a real world study (VOTE): evidence from discrete choice experiments. Poster presented at the 2020 Virtual 74th American Epilepsy Society (AES) Annual Meeting; December 4, 2020.

Dorgali MV, Longo A, Vass C, Shields G, Harrison R, Boeri M. Exploring Antimicrobial Resistance (AMR) from a societal perspective: preferences and welfare impacts in the United Kingdom. Poster presented at the Virtual ISPOR Europe 2020 Conference; November 2020. [abstract] Value Health. 2020 Dec; 23(S2).

Boeri M, Sutphin J, Hauber B, Cappelleri JC, William R, DiBonaventura D. Quantifying patient preferences for systemic atopic dermatitis treatments using a discrete choice experiment. J Dermatolog Trea. 2020 Nov 2;1-10. doi: 10.1080/09546634.2020.1832185

Boeri M, Sutphin J, Hauber B, Cappelleri JC, Romero W, DiBonaventura M. Identifying patient preferences for systemic atopic dermatitis treatments using a discrete choice experiment. Poster presented at the 2020 Virtual 29th European Academy of Dermatology and Venerology Congress; October 28, 2020.

McFerran E, Boeri M, Kee F. Patient preferences in surveillance: findings from a discrete choice experiment in the "My Follow Up" study. Value Health. 2020 Oct;23(10):1373-83. doi: 10.1016/j.jval.2020.05.015

Mansfield C, Sutphin J, Boeri M. Assessing the impact of excluded attributes on choice in a discrete choice experiment using a follow-up question. Health Econ. 2020 Oct;29(10):1307-15. doi: 10.1002/hec.4124

McMichael AJ, Rolison JJ, Boeri M, Kee F. The needs of many vs. the needs of few: is society willing to pay for stratified medicine. Poster presented at the 2020 36th ICPE International Virtual Conference on Pharmacoepidemiology & Therapeutic Risk Management; September 16, 2020.

Turk DC, Boeri M, Abraham L, Atkinson J, Bushmakin A, Cappelleri JC, Hauber B, Klein K, Russo L, Viktrup L, Walsh DA. Patient preferences for osteoarthritis pain and chronic low back pain treatments in the United States: a discrete-choice experiment. Osteoarthritis Cartilage. 2020 Sep 1;28(9):1202-13. doi: 10.1016/j.joca.2020.06.006

Graham-Clarke PL, Hauber B, Boeri M, Leonardi F, Burge RT, Fernandez M, Tockhorn-Heidenreich A, Florez S. Patient preferences for biologic and biosimilar osteoporosis treatments in Colombia. Patient Prefer Adherence. 2020 Jun 23;2020(14):1049-64. doi: 10.2147/PPA.S250745

Minnis AM, Atujuna M, Browne EN, Ndwayana S, Hartmann M, Sindelo S, Ngcwayi N, Boeri M, Mansfield C, Bekker L-G, Montgomery ET. Preferences for long‐acting Pre‐Exposure Prophylaxis (PrEP) for HIV prevention among South African youth: results of a discrete choice experiment. J Int AIDS Soc. 2020 Jun 16;23:e25528. doi: 10.1002/jia2.25528

Boeri M, Saure D, Schacht A, Riedl E, Hauber B. Modeling heterogeneity in patients' preferences for psoriasis treatments in a multicountry study: a comparison between random-parameters logit and latent class approaches. Pharmacoeconomics. 2020 Jun;38(6):593-606. doi: 10.1007/s40273-020-00894-7

Boeri M, Heidenreich S, Marshall D. We are not all the same: the state of practice in accounting for preference heterogeneity. Presented at the 2020 ISPOR Virtual Conference; May 18, 2020.

Vass C, Boeri M, Poulos C. Association between access device and stated preferences for health care. Poster presented at the 2020 ISPOR Virtual Conference; May 2020. [abstract] Value Health. 2020 May 1;. doi: 10.1016/j.jval.2020.04.1183

Browne EN, Montgomery ET, Mansfield C, Boeri M, Mange B, Beksinska M, Schwartz JL, Clark MR, Doncel GF, Smit J, Chirenje ZM, van der Straten A. Efficacy is not everything: eliciting women's preferences for a vaginal HIV prevention product using a discrete-choice experiment. AIDS Behav. 2020 May;24(5):1443-51. doi: 10.1007/s10461-019-02715-1

Poulos C, Vass C, Klein K, Boeri M. Scope tests in health care discrete choice experiments. Poster presented at the 2020 ISPOR Virtual Conference; May 2020. [abstract] Value Health. 2020 May 1; 23(Suppl 1):S320. doi: 10.1016/j.jval.2020.04.094

Mansfield C, Boeri M, Coulter J, Baranowski E, Sparks S, Hamed A. Preferences for genetic tests: trading off speed of diagnosis, availability of treatment, and cost. Poster presented at the 2020 ISPOR Virtual Conference; May 2020. [abstract] Value Health. 2020 May 1; 23(Suppl 1):S345. doi: 10.1016/j.jval.2020.04.094

Boeri M, Abraham L, Hauber B, Atkinson J, Bushmakin AG, Cappelleri JC, Russo L, Viktrup L, Klein K, Walsh D, Turk D. Exploring heterogeneity in preferences for attributes of pharmaceutical treatments for osteoarthritis and chronic low back pain in the United States: a latent class approach. Presented at the 2020 ISPOR Virtual Conference; May 18, 2020. [abstract] Value Health. 2020 May 1; 23(Suppl 1):S325. Previously presented at the ISPOR 2019 European Conference. doi: 10.1016/j.jval.2020.04.371

Sutphin J, Boeri M, Hauber B, Purdum AG. Physician preferences for CAR T therapy: trading off benefits, risks, and time to infusion in the treatment of diffuse large B-cell lymphoma. Poster presented at the 2020 ISPOR Virtual Conference; May 2020. [abstract] Value Health. 2020 May 1; 23(Suppl 1):S19. doi: 10.1016/j.jval.2020.04.094

Sutphin J, Mansfield C, DiSantostefano R, Klein K, Boeri M. Getting the most out of latent-class analysis in modeling preferences for an interception treatment in Type 1 diabetes. Poster presented at the 2020 ISPOR Virtual Conference; May 2020. [abstract] Value Health. 2020 May 1; 23(Suppl 1):S125. doi: 10.1016/j.jval.2020.04.371

Boeri M, Stojanovic TA, Wright LJ, Burton NHK, Hockley N, Bradbury RB. Public preferences for multiple dimensions of bird biodiversity at the coast: insights for the cultural ecosystem services framework. Estuar Coast Shelf Sci. 2020 Apr 5;235:106571. doi: 10.1016/j.ecss.2019.106571

Mansfield C, Poulos C, Boeri M, Hauber B. Performance of a comprehension question in discrete-choice experiment surveys (DCE). Poster presented at the ISPOR 2019 European Conference; November 5, 2019. Copenhagen, Denmark. [abstract] Value Health. 2019 Dec; 22(S3).

Boeri M, Saure D, Schuster C, Hill J, Guerreiro M, Hauber B. Do clinical and demographic characteristics affect patient preference heterogeneity for psoriasis treatments? Results from a discrete-choice experiment in a multicountry study. Poster presented at the ISPOR 2019 European Conference; November 4, 2019. Copenhagen, Denmark. [abstract] Value Health. 2019 Dec; 22(S3). doi: 10.1016/j.jval.2019.09.267

Boeri M, Abraham L, Hauber B, Atkinson J, Bushmakin AG, Cappelleri JC, Russo L, Viktrup L, Walsh D, Turk D. Exploring heterogeneity in preferences for attributes of pharmaceutical treatments for osteoarthritis and chronic low back pain in the United Kingdom; a latent class approach. Presented at the ISPOR 2019 European Conference; November 5, 2019. Copenhagen, Denmark. [abstract] Value Health. 2019 Nov 1; 22(Supplement 3):S923. doi: 10.1016/j.jval.2019.09.2738

Augustin M, Feldman S, Poulos C, Gilloteau I, Mange B, Boeri M, Boehm K, Melzer N, Gutknecht M. Patient preferences for treatment of moderate to severe psoriasis: a discrete choice experiment study in Germany. Poster presented at the 28th European Academy of Dermatology and Venereology (EADV) Congress; October 11, 2019. Madrid, Spain.

Turk D, Boeri M, Abraham L, Hauber B, Atkinson J, Bushmakin AG, Cappelleri JC, Russo L, Viktrup L, Walsh DA. Patient preferences for attributes of treatments for chronic pain associated with osteoarthritis pain and chronic low back pain that differentiate nerve-growth factor inhibitors, nonsteroidal anti-inflammatory drugs, and opioids in the US: a Discrete-Choice Experiment (DCE). Presented at the 2019 ACR/ARP Annual Meeting; November 12, 2019. Atlanta, GA. [abstract] Arthritis Rheumatol. 2019 Oct; 71(suppl 10). doi: 10.1002/art.v71.s10